MRK•benzinga•
Merck's Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared To Intravenous KEYTRUDA In Pivotal 3475A-D77 Trial; A Time And Motion Descriptive Analysis Shows Nearly 50% Reductions In Pat
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 27, 2025 by benzinga